Biogen Research Triangle Park Expansion

Deal value: $2,000,000,000

Biogen committed $2B to expand its manufacturing operations in North Carolina’s Research Triangle Park, enhancing production of MS and Alzheimer’s therapies and adding advanced biotech modalities.

Biogen’s $2B expansion in Research Triangle Park is driven by the need to support its late-stage clinical pipeline, particularly for MS and Alzheimer’s therapies, and to modernize manufacturing with advanced biotech modalities. The investment reflects a belief in sustained demand for innovative biologics and the strategic importance of resilient, U.S.-based supply chains. The timing aligns with industry-wide trends of reshoring manufacturing and scaling capacity to meet both current and anticipated therapeutic needs.